Prediction of Histopathologic Response of Primary Breast Cancer by Relative Changes in 18F-FDG Uptake on 18F-FDG PET

Tumor type or stageStudyYearNo. of patientsPET timingPET criterion*AccuracyResponse rate
LABCSchelling et al. (38)200022After first cycle55%88%7/22 (29%)
After second cycle55%91%
Large (>3 cm) and LABCSmith et al. (39)200030After first cycle20%§80% (sens, 90%; spec, 74%)11/30 (38%)
Stages II and IIIRousseau et al. (40)200664After first cycle40%77%36/64 (56%)
After second cycle40%87%
Large (>3 cm) and LABCMcDermott et al. (41)200796After first cycle24%65% (sens, 100%; spec, 53%)13/51 (25%)
Midtherapy58%78% (sens, 100%; spec, 68%)14/45 (31%)
Large (>3 cm) and LABCSchwarz-Dose et al. (42)2008104After first cycle45%65%17/104 (16%)
After second cycle55%64%
LABCDunnwald et al. (59)200853Midtherapy (9 wk after initiation)5% increase in tumor blood flow (vs. 5% decrease)Hazard ratio, 1.7 (P < 0.001)Overall survival
  • * Reported as cutoff for relative decrease in SUV, unless otherwise indicated.

  • Accuracy of 18F-FDG PET for prediction of histopathologic response. sens = sensitivity; spec = specificity.

  • Outcome measure was histopathologic response.

  • § 18F-FDG uptake was measured as dosage uptake rate instead of SUV.

  • Value was not given in publication; accuracy was calculated on basis of sensitivity, specificity, and response rate.

  • Pathologic response rate among patients who underwent PET at indicated point in therapy; overall response rate was not given.

  • LABC = locally advanced breast cancer.

  • All studies summarized in this table were prospectively designed.